.Merck trumps incomes requirements, increases sales expectation on strong requirement for leading medications like Keytruda CNBCMerck & Co. (MRK US) Defeats Profit Estimates as Keytruda Sales Increase BloombergMerck Stock: Pharma Titan Posts Tough Outcomes, However Outlook Tumbles Short Investor's Service DailyMerck Announces Second-Quarter 2024 Financial End results Yahoo FinanceMerck defeats earnings and also sales desires amidst Keytruda strength, yet gives mixed full-year outlook MarketWatch.